Current and Emerging Strategies to Inhibit Type 2 Inflammation in Atopic Dermatitis

Abstract

Type 2 immunity evolved to combat helminth infections by orchestrating a combined protective response of innate and adaptive immune cells and promotion of parasitic worm destruction or expulsion, wound repair, and barrier function. Aberrant type 2 immune responses are associated with allergic conditions characterized by chronic tissue inflammation, including atopic dermatitis (AD) and asthma. Signature cytokines of type 2 immunity include interleukin (IL)-4, IL-5, IL-9, IL-13, and IL-31, mainly secreted from immune cells, as well as IL-25, IL-33, and thymic stromal lymphopoietin, mainly secreted from tissue cells, particularly epithelial cells. IL-4 and IL-13 are key players mediating the prototypical type 2 response; IL-4 initiates and promotes differentiation and proliferation of naïve T-helper (Th) cells toward a Th2 cell phenotype, whereas IL-13 has a pleiotropic effect on type 2 inflammation, including, together with IL-4, decreased barrier function. Both cytokines are implicated in B-cell isotype class switching to generate immunoglobulin E, tissue fibrosis, and pruritus. IL-5, a key regulator of eosinophils, is responsible for eosinophil growth, differentiation, survival, and mobilization. In AD, IL-4, IL-13, and IL-31 are associated with sensory nerve sensitization and itch, leading to scratching that further exacerbates inflammation and barrier dysfunction. Various strategies have emerged to suppress type 2 inflammation, including biologics targeting cytokines or their receptors, and Janus kinase inhibitors that block intracellular cytokine signaling pathways. Here we review type 2 inflammation, its role in inflammatory diseases, and current and future therapies targeting type 2 pathways, with a focus on AD. Infographic Supplementary Information The online version contains supplementary material available at 10.1007/s13555-022-00737-7.

Successful treatment of lichen amyloidosis coexisting with atopic dermatitis by dupilumab: Four case reports

“…A familial study of some cases of PCA has revealed mutations in both genes encoding the subunits of IL-31 receptors (IL31RA and OSMR β)[ 15 ]. It has been demonstrated that IL-4, IL-13, and IL-31 are associated with sensory nerve sensitization and itching in AD patients, leading to scratching that further exacerbates inflammation and barrier dysfunction[ 16 ]. IL-31 is significantly overexpressed in the skin samples of patients with AD.…”

A Systematic Review of Atopic Dermatitis: The Intriguing Journey Starting from Physiopathology to Treatment, from Laboratory Bench to Bedside

“…Alongside these innovative research fields, approaches based more classically on the use of molecularly targeted drugs capable of modifying the inflammatory pathway of AD, acting on several key molecules, such as IL-1α, IL5, IL17, IL25, TLSP, IL31 and IL33, are being researched. Again, the progression in knowledge of the processes underlying the inflammatory cascade has led to the identification of specific and effective molecular targets, whose blockade may improve many features of disease, including pruritus, inflammation, skin barrier disruption and skin colonization [ 84 , 85 ].…”

Therapeutic DNAzymes: From Structure Design to Clinical Applications

“…The World Health Organization lists chronic inflammatory diseases as the most cause of death, [204] considering type 2 inflammation as the main manifestation. For example, asthma [205] (>50%), ulcerative colitis, chronic obstructive pulmonary disease (COPD), and atopic dermatitis [206] are all related to type 2 inflammation. GATA3 is an ideal target to treat type 2 inflammatory disease.…”